The TT2016 13th meeting of the International Society for Transgenic Technologies (ISTT) was held in the beautiful, historic city of Prague, Czech Republic on March 20-23, 2016. The meeting was hosted by Radislav Sedlacek (chair, Institute of Molecular Genetics of the ASCR, Prague, Czech Republic) in association with the Czech Academy of Sciences. This meeting assembled more participants than any of the past TT meetings with a total of more than 700 researchers, students and technicians from close to 40 countries around the world. The venue for the meeting was the very modern Clarion Congress Hotel Prague and was organized by Guarant International who did a superlative job and who were continuously available to be of service to delegates, speakers and vendors resulting in a smooth, well-run conference.
CRISPR/Cas technology continues to be a major focus of our meetings as evidenced by its inclusion in a number of talks in several of the 16 varied sessions over the course of the three plus day conference. Other topics under the umbrella of transgenic technology ranged from new approaches in designing CRISPR/ Cas reagents to nanoinjection of nucleases into hundreds of cells at once to large animal technology. Presentations covered the use of the epigenome to target the ''regulome''; examination of non-coding regions of the genome; phenotypic analysis by large consortia; methods for increasing the number of ovulated mouse oocytes; gene drive advances; noninjection techniques; and the history and ethics of using guided nuclease technology. Overall, the scientific program was exceptional! There were a number of new initiatives at TT2016. We had orbis pictus lectures-lectures designed to use pictures and clear descriptions to demonstrate answers to a problem. Also, for the first time, we had concurrent sessions where delegates chose whether to hear about ethics in animal use, or new injection and superovulation techniques. Introduced this year, the Opening Session of the meeting began with a Keynote Lecture presentation on Sunday evening followed by an informal come-together buffet dinner complete with traditional Czech music. This created an excellent opportunity to meet, get reacquainted, and socialize with fellow delegates the evening before the main meeting started. The ongoing poster session in a designated room made for easy access and availability for delegates to peruse at their leisure.
The welcome address was given by Radislav Sedlacek, Chair of the 13th Transgenic Technology meeting, who pointed out that Charles University in Prague is one of the oldest universities in Europe, making Prague a fitting location for a mostly academic and research oriented conference such as this.
Andras Nagy (Mount Sinai Hospital, Toronto, Canada) opened the meeting with an excellent Keynote Lecture describing using transposon delivered transgenes to better understand cellular programming. Andras gave a short history of his and others' achievements in the area of site specific nucleases and iPS cells and using this technology to study cell therapy.
The first morning of the general meeting included two sessions on the Generation of Transgenic Models. Charles Gersbach (Duke University, Durham, USA) started off the session by discussing use of CRISPR/ Cas9 technology for gene therapy and disease modelling. His studies included injecting CRISPRs targeting a specific exon via AAV directly into the muscle to make diseases such as Duchenne muscular dystrophy less severe. Another therapeutic tool is to use ''dead'' Cas9 and later activate it by injecting an activation domain. Ralf Kuehn (Max-Delbruck-Center for Molecular Medicine, Berlin, Germany) talked about the ''perfect protocol'' for homology directed repair (HDR) that we are all trying to achieve and discussed optimization of CRISPR/Cas9 injections into mouse embryos. Thankfully he has designed ROSA targeting vectors that he has made available at Addgene and has produced mice that either conditionally or constitutively express Cas9 which are available at Jackson Labs. Lluis Montoliu (Centro National de Biotecnologia, Madrid, Spain) rounded out the first session with his interesting discussion on using CRISPR/Cas9 technology to study non-coding areas of the DNA, which happens to account for 98 % of the genome. He uses CRISPR/Cas to target non-coding regulatory elements of tyrosinase, a gene affected in human albinism.
The second session of the morning was comprised of several selected presentations chosen by the organizing committee for full presentation. We started with a talk by Severine Menoret (Association ITERTUN, Nantes, France) who presented her protocols on increasing efficiency of BAC transgenesis by using piggybac transposons rather than CRISPR/Cas9. Grzegorz Kreiner (Institute of Pharmacology, PAS, Krakow, Poland) discussed a novel approach to generating transgenic mice by targeting the nucleolus to downregulate ribosomal RNA to study aging and specifically Alzheimer's disease. Melissa Larson (University of Kansas Medical Center, Kansas City, USA) talked about pronuclear transfer between strains of mice to study mitochondrial DNA which when mutated can lead to cancer. Christian Mosimann (University of Zurich, Zurich, Switzerland) was the first presenter to use zebrafish as a model in his injections of ribonucleoproteins. He introduced us to a novel iPhone App for data acquisition of zebrafish behavior. Andrei Golovko (Texas A&M Institute for Genomic Medicine, College Station, USA) gave an update on the TIGM (Texas A&M Institute for Genomic Medicine) database and repository including discussions of the traditional retroviral genetrap technology and newer mice available with mutations in long noncoding RNA's. Anna Anagnostopoulos (The Jackson Laboratory, Bar Harbor, USA) discussed using the HMDC (Human-Mouse: Disease Connection) portal in the MGI (Mouse Genome Informatics) database to look at human-mouse connections to identify appropriate mouse models of human disease.
There were two sponsored lectures during the lunch session, one given by Caroline Beckett, the CRISPR Product Manager at Merck, Sigma-Aldrich Chemie GmbH and the other presented by Jean Cozzi of Charles River and Guillaume Pavlovic of Phenomin ICS. Both discussed how their company and its research can help with designing specific genetic mutations for your particular project.
The afternoon Roundtable format focused as usual on Running a Transgenic Service Facility and included short presentations from directors of four transgenic cores: Cord Brakebusch from the University of Copenhagen, Denmark; Ignacio Anegon from the Transgenic Rats ImmunoPhenomics Facility in Nantes, France; Marina Gertsenstein from the Centre for Phenogenomics in Toronto, Canada; and Lauryl Nutter from the Centre for Phenogenomics also in Toronto, Canada. Each speaker contributed procedures that worked well for them, insights into making their cores run more efficiently, and stimulated much lively discussion from fellow delegates, especially regarding CRISPR/Cas injections.
Monday afternoon continued with Session 4 focusing on large scale phenotype screening including analysis of lethal mutations using 3D imaging and microCT, a presentation by Mary Dickinson (Baylor College of Medicine, Houston, USA). Nicholas Gale (Regeneron Pharmaceuticals, Tarrytown, USA) talked about using large scale phenotyping screens to discover novel targets to tumors specifically in the vascular system. Kent Lloyd (Mouse Biology Program, Davis, USA) rounded out the session by updating us on the progress of the International Mouse Phenotyping Consortium (IMPC).
Session 5, chaired by Lluis Montoliu, concentrated on discovery and development of novel CRISPR/Cas systems. Francis Mojico (University of Alicante, Alicante, Spain) gave a history of the discovery and usefulness of the CRISPR/Cas system and its adaptability to be used as a genetic tool in all organisms. Bernd Zetsche (Broad Institute, Cambridge, USA), from the lab of Feng Zhang, introduced us to a new RNA-guided nuclease, Cpf1 which was discovered in the Zhang lab. Konstantin Severinov (Skolkova Institute of Science and Technology, Moscow, Russia) went on to discuss a pipeline approach to discovering even more CRISPR/Cas-like systems and variants of the system to increase efficiency and specificity.
The second full day of TT2016 started with two sessions on Advances in Animal Biotechnology highlighting farm animal transgenesis and the establishment of a communication platform (SALAAM) in Europe. Presentations included achievements in applying new and old transgenic tools to improve the efficiency in transgene expression, and using gene KO/ KI in order to gain desired phenotypes, produce human disease models, or generate xenorejection resistant pig organs. The first speaker Eckhard Wolf (LMUMunich, Munich, Germany) presented the EU COST Action Sharing Advances on Large Animal Models (SAL-AAM), in which a number of ISTT members participate. SALAAM aims to share information to develop standardised protocols and databases on large animal models and communicate this to the academic, medical and commercial communities. He also highlighted his progress in DMD and diabetic pig models. This was followed by Yonglun Alun Luo (Aarhus University, Aarhus, Denmark) who continued the theme of large animal human disease models, specifically ''handmade pig cloning'' that have been developed in Denmark, including an elegant description of various genome editing strategies. The third talk in this session was by Chris Proudfoot (Roslin Institute, Midlothian, UK) who brought us up to speed on the progress achieved with the different genome editors in livestock to make human disease models or gain a desired phenotype. SooYoung Yum (Seoul National University, Seoul, South Korea) presented their data in the generation and analysis of transgenic cattle with injection of piggybac (PB)-GFP DNA into zygotes derived from in vitro fertilization. Wiebke Garrels (Hannover Medical School, Hannover, Germany) presented a highly efficient method for the generation of multi transgenic cattle produced via the Sleeping Beauty (SB) transposon system in combination with cytoplasmic plasmid injection. Amy Kaucher (Washington State University, Pullman, USA) gave a talk about the injection of CRISPR/Cas9 reagents into in vivo derived porcine 1-cell embryos in order to specifically disrupt the Nanos2 gene resulting in ablation of germline cells in male pigs. Sean Stevens (Synthetic Genomics, Inc., La Jolla, USA) shared the strategies and recent progress in creating genetically modified pigs to combat xenorejection through different pathways for the purpose of generating humanized pig organs for xenotransplantation.
Session 8 was comprised of two parallel sessions; one on Animal Ethics and the other on Technology Development. This year's meeting featured a dedicated session on animal ethics. Although the session had to compete in parallel with a session on highly debated new technologies, it drew a respectable number of interested delegates. Henriette Bout (ConScience, Amsterdam, The Netherlands), unique to a TT meeting by not being a natural scientist but a humanist, started the session with ethical considerations on our relation to nature and to animals. She involved the audience and demonstrated how diverse ethical values can be even within an audience working with experimental animals on a daily basis. Aurora Brønstad (University of Bergen, Bergen, Norway) continued with a report on a harm benefit analysis jointly developed by AALAS and FELASA. She introduced a tool that has been developed to objectify the process of ethical considerations in weighing the harm inflicted on animals against the potential benefit of a study, an issue with which scientists, local ethical committees, as well as competent authorities continue to struggle with. The session was finalized with a lecture by Michelle Stewart (Medical Research Council, Didcot, UK) on ways to improve the quality of data extracted from animal experimentation with a strong focus on phenotyping genetically altered mice. It is the 4Rs of phenotyping that count: robustness, reproducibility, rigorousness, and randomization.
The Technology Development parallel session included a talk by Toru Takeo (Kumamoto University, Kumamoto, Japan) on a more efficient method of superovulation to increase production of mouse oocytes using inhibin antiserum and equine chorionic gonadotropin. Jeff Batton (GeneSearch, Inc., Bozeman, USA) described innovative new designs of microtools for holding, injecting, and sampling of biopsies for difficult to handle preimplantation embryos. Sandra Hope (Brigham Young University, Provo, USA) portrayed a pioneering nanoinjection system that can deliver CRISPR/Cas reagents to hundreds or thousands of cells simultaneously.
A second day lunch session presented by Ruby Yanru Chen-Tsai from Applied StemCell, Inc. described using TARGATT technology to engineer the genomes of rats, rabbits and pigs in addition to mice.
In session 9, titled ''Gene Manipulation and Genome Editing and (disease) Models I, we had two stimulating talks on how CRISPR/Cas9 is being used both in ''active genetics'' (i.e. gene drive) and to induce deleterious mutations. Valentino Gantz (University of California San Diego, La Jolla, USA) discussed his recent work in establishing gene drive mechanisms in Drosophila essentially causing a mutagenic chain reaction and how this could be utilized to reduce/eliminate disease-causing insects. This was followed by a talk by Didier Stanier (Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany) who used CRISPR/Cas9 to induce mutations in zebrafish that compromised the Egf17 gene and found that total gene knockout would result in genetic compensation whereas knockdowns by morpholinos do not. This has implications for mutant models of diseases that are caused by mutation rather than by reduction of protein product. Session 10, a continuation of the Disease Models topics, started off with a presentation from Tania Sorg-Guss (CERMB-BIE, Illkirch, France) who was standing in for Yann Herault (PHENOMIN, Illkirch, France). She described GENCODYS which is a research consortium funded by the European Union dedicated to discover the functions and dysfunctions of the brain. They are using next generation sequencing to identify genes associated with low IQ in humans using mouse models. Katherina Boroviak (The Welcome Trust Sanger Institute, Cambridge, UK) discussed the limitations and possibilities of CRISPR/Cas technology including large chromosomal rearrangements and small insertions via cytoplasmic injection, resulting in inversions, duplications and point mutations. Kevin Peterson (The Jackson Labs, Bar Harbor, USA) described using CRISPR/Cas mediated gene modification to generate mouse models of human developmental disorders.
TT2016 saw the initiation of a new type of lecture-the orbis pictus lecture, designed to clearly describe a topic with encyclopedic discussion and clear demonstrative pictures. The first orbis pictus lecture was given by Richard Behringer (University of Texas, MD Anderson, Houston, USA) who described the wide variety of methods of making transgenic animals in a vast array of animal species. From mosquitos and bees to worms to chickens to cows, Richard showed how the physiology of the egg/oocyte would affect the method used to make a genetic modification. This was an excellent lecture that demonstrated the diversity of our community of scientists and technicians who are asked to generate new animal models.
The ISTT, Inc. held its third General Assembly just prior to the Gala Dinner. During the meeting, we sadly said goodbye to three departing Board members: Tom Fielder, Boris Jerchow and Wojtek Auerbach. We also reviewed ISTT finances, membership, committee activities, and interactions with our affiliated organizations. One new ISTT initiative that was presented was an outreach committee to our members (and nonmembers) who perform transgenic technologies in non-rodent (generally large animal) species. The ISTT large animal group will be headed by Martina Crispo and Bruce Whitelaw. The General Assembly meeting ended with a presentation inviting members to attend TT2017 in Salt Lake City, Utah, USA, hosted by Susan Tamowski.
Following the General Assembly delegates enjoyed the customary Gala Dinner that proved to be the high point of the social program. Zofin Palace was full with partygoers, wine flowed freely, the food was wonderful, and the string quartet (plus clarinet) fantastic as well.
On the last day of the meeting, the latest technological advances were presented in session 11, Technology Development II, a highly anticipated session by meeting participants, as there were many microinjectionists in attendance. The presentations started with Masato Ohtsuka (Tokai University, Isehara, Japan). He talked about several new technologies for creating mutant mouse lines including improved Pronuclear Injection-based Targeted Transgenesis (i-PITT) an efficient one-step method for targeting multiple transgenes simultaneously in the ROSA26 locus. The second method, Genome-editing via Oviductal Nucleic Acids Delivery (GONAD) allows efficient CRISPR/Cas9 gene editing in day 0.7 and 1.5 embryos directly in the oviduct, eliminating the need for isolation, microinjection and surgical transfer of embryos. The ease of this technique makes CRISPR/ Cas9 gene-editing in embryos feasible for laboratories with limited transgenic resources. The third technique, dubbed Easy (Isi)-CRISPR uses ssDNA donors synthesized by in vitro transcription and reverse transcription (ivTRT) to achieve high efficiency CRISPRmediated insertions. The second talk of the session was presented by Haoyi Wang (Chinese Academy of Sciences, Beijing, China). He talked about recent optimizations to the Zygote Electroporation of Nuclease (ZEN) protocol, including use of Cas9 protein and multiple electroporations, which significantly improve the generation of targeted point mutations, short segment insertions, and large genomic segment deletions. In addition, he described an adaptation of CRISPR technology that can be used to modify or regulate gene expression, or label chromosomes. The Casilio system (a combination of Cas9 and Pumilio) is comprised of nuclease deficient Cas9 (dCas9), sgRNA appended with specific 8-mer binding sites, and effector molecules fused with a programmable Pumilio/FBF RNA-binding domain. This important achievement allows specific and independent delivery of effector proteins to specific genomic loci. Last but not least, Tomomi Aida (Tokyo Medical and Dental University, Tokyo Japan) talked about his Cloningfree CRISPR/Cas9 system for generating knock-in mice carrying larger targeted insertions. Using dual RNAs (crRNA and tracrRNA, which due to their length, can be chemically synthesized) and Cas9 protein, they were able to obtained knock-in mice carrying a precisely integrated 2.5 Kb Flex switch cassette with high efficiency. This system was also used to efficiently insert a 2.5 kb in-frame fusion cassette. In addition to improved HR efficiency, this novel technology results in efficient germline transmission, less mosaicism and fewer off-target mutations. Aida also talked about two other technologies for creating mutations: PITCh (Precise Integration into Targeted Chromosome) system, which capitalizes on microhomology-mediated end-joining (MMEJ) DNA repair mechanisms to create precise gene knock-ins; and BAC-In with 2H2OP technology which enables site-specific insertion of BAC DNA to create chromosomally ''humanized'' alleles. In conclusion, the development of these associated technologies to the already efficient CRISPR/Cas system enables the generation of multiple gene edited animal models in a fast and simple manner never achieved before.
Session 12 titled Genetics, Epigenetics, Stem Cell Manipulation started off with a presentation by Robin Lovell-Badge (The Francis Crick Institute, London, UK) who discussed the regulation of Sox9, the transient expression of SRY, and other genes involved in testes development and sex determination. Kent Hamra (University of Texas Southwestern Medical Center, Dallas, USA) discussed making genetic modifications using CRISPR/Cas in rat spermatogonial stem cell cultures and transplanting these into rat testes to produce transgenic animals. John Schimenti (Cornell University, Ithaca, USA) uses a novel approach called GWIS which uses the CRISPR/Cas system to find deleterious SNP's involved in human reproductive genes.
A third session on Generation of Transgenic Models began with Marie-Christine Birling (CERMB-GIE, Illkirch, France) discussing the generation of mouse models of human intellectual disability (ID) using genetic variants with the help of the International Mouse Phenotyping resource. Petr Kasparek (Institute of Molecular Genetics, Prague, Czech Republic) used TALENs to inactivate three genes involved in human Netherton syndrome and rescue a lethal phenotype in mice. Javier Martin-Gonzalez (University of Copenhagen, Copenhagen, Denmark) spoke about optimal methods for producing NRG embryonic stem cell lines. Prem Premsrirut (Mirimus, Inc., Woodbury, USA) uses inducible CRISPR/Cas along with inducible RNAi to develop mice that mimic human disease with the goal of drug discovery and drug therapy.
Thomas Boehm (Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany) gave the second orbis pictus lecture focusing on the genetic basis of lymphoid organ formation. In an iterative process, his team has used comparative genomics of chordates, genetic screens in zebrafish, and transgenic modifications in zebrafish and mice in order to functionally characterize developmental checkpoints of thymus and T cell development. Based on this information, they succeeded in reconstructing the hypothetical haematopoietic properties of the thymus of extinct pre-vertebrates and generating minimalistic thymopoietic tissues in vivo. His presentation highlighted the importance of combining different type of animal models (from lamprey to zebrafish to mice) for understanding complex genetic processes, such as those governing immune system development and function, with a view to explaining human disease and to developing targeted therapies for correcting failing immune function.
The 14th session focused on iPS cells and pluripotency. Rene Maehr (UMass Medical School, Worcester, USA) talked about using iPS cells from the thymus to study autoimmune diseases with the intention of improving personalized medicine. Ron Weiss (Massachusetts Institute of Technology, Cambridge, USA) introduced us to a new field of synthetic biology that uses microfluidic chips, genetic circuits and modules, and artificial cell-cell communication with the hope of using biomarkers to influence behavior of cell populations.
On the last day, the ISTT Young Investigator Award (sponsored by inGenious Targeting Laboratory) was presented as well as the Best Poster Awards. The ISTT Young Investigator Award was given to Pablo Ross (University of California Davis, Davis, USA) based on his work developing ES cells in farm animals. He was trying to engineer interspecies chimeric blastocysts towards making use of pigs to grow human organs. The Best Poster Awards were selected by a committee of ISTT members who chose from more than 125 posters that were displayed throughout the meeting in the spacious poster room. Denis Duboule (University of Geneva, Geneva, Switzerland), invited for the closing keynote lecture, gave a fascinating update on sophisticated genetic approaches developed in his laboratories for unraveling long-range gene regulation mechanisms during development and evolution. His research activities are aimed at dissecting the genetics of murine Hox loci, either by using established mouse genetic manipulations, or by designing and implementing new powerful chromosome engineering strategies. Hoxd genes appear to be amongst the key players in the emergence and evolution of digits. Denis' team made use of crelox as well as CRISPR/Cas to delete parts of the hoxd cluster, induce inversions or translocations of the gene, or even disrupt enhancers outside of the hox cluster and was able to see affects in digits and the forearm. These discoveries in the functional deployment of HOX proteins and their impacts upon the emergence of novel structures in the course of vertebrate phylogeny illustrate how transgenic genomes and subtle genome engineering can help to understand complex regulatory modalities.
The meeting ended with a presentation by Susan Tamowski (University of Utah, Salt Lake City, USA) who introduced the site of TT2017 to be held at Snowbird Ski and Summer Resort in the mountains above Salt Lake City, Utah, USA and invited all to attend the next ISTT meeting.
As always, there were hands-on workshops associated with the TT meeting available to delegates either immediately before or after the regular ISTT conference. The meeting was preceded by two workshopsone on programmable nucleases (headed by Radislav Sedlacek) and one on cryopreservation (led by Martin Fray, INFRAFRONTIER). Following the meeting was one additional workshop on zebrafish transgenesis (lead by Petr Bartunek, Zbynek Kozmik, Christian Mosimann and Graham Lieschke). Those who attended the workshops were very pleased with the learning opportunities that were afforded them. All three workshops were well-attended and greatly appreciated! ''Overall, TT2016 can be considered as one of the best TT meetings ever, and I am proud, as ISTT President, that we helped to host such a wonderful meeting. Thanks so very much to the organizersRadislav Sedlacek, Inken Beck and Nicole Chambers. Due to their amazing work, the ISTT has again had a successful TT meeting!'' quote from Jan ParkerThornburg, President of ISTT.
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